Loading...
•
Jul 31, 2022
KalVista Q1 2023 Earnings Report
KalVista reported first fiscal quarter results, with KVD824 Phase 2 clinical trial reaching 50% enrollment and an open label extension study initiated for sebetralstat.
Key Takeaways
KalVista Pharmaceuticals reported no revenue for the first fiscal quarter ended July 31, 2022. Research and development expenses increased to $18.2 million, and general and administrative expenses rose to $8.1 million. The net loss for the quarter was $23.0 million, or $(0.94) per share. Cash, cash equivalents, and marketable securities totaled $142.1 million as of July 31, 2022.
KVD824 KOMPLETE Phase 2 clinical trial reached 50% enrollment milestone.
KONFIDENT-S open label extension study was initiated for sebetralstat.
Enrollment is proceeding as expected for the Phase 3 KONFIDENT trial for sebetralstat, with data expected in the second half of 2023.
The Phase 2 KOMPLETE clinical trial for KVD824 also remains on track with its enrollment targets, with data expected in mid-2023.
Forward Guidance
The press release contains forward-looking statements regarding the timing and outcomes of clinical trials, the safety and efficacy of product candidates, and the ability to obtain regulatory approvals.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...